Here are the updates from Friday: The Department of Biotechnology on Friday clarified that the nasal Covid-19 vaccine, developed by biote...
Here are the updates from Friday:
- The Department of Biotechnology on Friday clarified that the nasal Covid-19 vaccine, developed by biotechnology company Bharat Biotech, has received the drug regulator’s nod to hold only the phase 2 trial, reported PTI. Earlier in a statement, the company said the department had said that it had received the nod to conduct phase 2 and phase 3 trials.
- India on Friday recorded 40,120 cases of Covid-19 in the past 24 hours, taking the cumulative tally to 3,21,17,826 since the pandemic began in January last year. The toll rose to 4,30,254 with the country reporting 585 fatalities in the past day.
- Global pharmaceutical company Wockhardt Limited said it has partnered with Human Vaccine LLC, a subsidiary of the Russian Direct Investment Fund, to produce and supply Sputnik V and Sputnik Light vaccines, reported the Hindustan Times.
- Serum Institute of India chairperson Cyrus Poonawalla expressed reservation against the mixing of Covid-19 vaccines. Poonawalla said that if two vaccines are mixed and results are not good, either of the manufactures of the shots can claim that the vaccine of the other company was not good. Poonawala also said that the ideal gap between two doses of Covishield is two months and another dose of the vaccine should be taken after six months,...
